In humans, mutations in the BCR-ABL fusion protein, commonly seen in chronic myeloid leukemia (CML), can confer resistance to tyrosine kinase inhibitors such as imatinib by altering the ATP-binding site of the kinase domain [83]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.